



July 10, 2015

Company Name	3 - D M a t r i x , L t d .
A d d r e s s	3-2-4, Kojimachi, Chiyoda, Tokyo
P r e s i d e n t	Kentaro Takamura
Code Number	7777
C o n t a c t	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

Partnership Agreement concluded with Daewoong Pharmaceutical Co., Ltd. regarding sales and marketing of absorbable local hemostat 「PuraStat®」 in ASEAN

The 3-D Matrix group is working towards commercialization of absorbable hemostat “PuraStat®” globally. The company hereby announces that the subsidiary in Singapore, 3-D Matrix Asia Pte. Ltd. (“3DMA”), and Daewoong Pharmaceutical Co., Ltd. (“DW”, head office located in Seoul, Korea, President & CEO Jong-Wook Lee) have entered into a partnership agreement for sales and marketing of our absorbable local hemostat “PuraStat®” in ASEAN on July 10th, 2015.

Based on this agreement, 3DMA will grant an exclusive sales and marketing license to DW in Thailand, Philippines and Vietnam, and a semi-exclusive sales and marketing license in Indonesia where 3DMA already has a local partner with PT. Teguhindo Lestartama (“TL”). 3DMA will receive milestone payments for granting these licenses.

This agreement will allow expansion of commercial sales in ASEAN through DW’s local networks. As for the exclusive sales and marketing license in Indonesia previously granted to TL, 3DMA has obtained agreement from TL to grant semi-exclusive sales and marketing license to DW, and the two companies will be working together to cater to expanding Indonesian market.

DW will be applying for product registration in Thailand, Philippines and Vietnam. Once registered, DW will then market the product within respective markets leveraging on their group’s local network. DW expects that “PuraStat®” will be registered by end of this fiscal year, and that commercial sales will take place by next fiscal year in Thailand, Philippines and Vietnam.

We will be registering revenue of approximately JPY 30,000,000 in the first quarter of this fiscal year due to the conclusion of this agreement. This revenue is already accounted for in the current business plan, and hence we do not expect significant impact on our earning forecast and “mid-term business plan” from this agreement at the moment.